Emerging studies suggest Retatru tide , a dual agonist targeting both incretin and another hormone, appears to represent a significant development for weight treatment. Initial human tests have indicated considerable reductions in visceral fat , potentially outperforming current obesity therapies . Despite this, further assessment is necessary to t